Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Celsion’s BPH treatment technology is acquired by Boston Scientific

Boston Scientific : 22 June, 2007  (New Product)
Boston Scientific has purchased technology for treating symptomatic benign prostatic hyperplasia (BPH, often referred to as enlarged prostate) from Celsion.
The Boston Scientific purchase follows approval of the acquisition by Celsion stockholders.

The purchase consists primarily of the Prolieve Thermodilatation System, which Boston Scientific has exclusively distributed since 2004.

Benign prostatic hyperplasia or BPH affects many men over the age of 50 and can have a significant impact on quality of life including a frequent need to urinate and pain or burning while urinating.

The Prolieve System is a non-surgical, less invasive, microwave based treatment for symptomatic BPH that is routinely performed in the physician's office.

The Prolieve System's transurethral Catheter uses microwave heating to reduce the enlarged prostate tissue and improve urine flow.

The Catheter also includes a dilatation balloon, a feature not available in other currently available microwave technologies for BPH.

The balloon is used to dilate, or open, the prostatic urethra during the microwave treatment.

'The acquisition of the Prolieve System results from the successful four year relationship between Boston Scientific and Celsion', said Eric Goorno, president of Boston Scientific's Urology/Gynaecology business.

'This purchase demonstrates Boston Scientific's continued commitment to improving treatment options for those suffering from urologic conditions, including BPH'.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo